Copyright(c)2019 Qilu Pharmaceutical Co., Ltd. 鲁ICP备06006222号

Headquarter Address: 8888 Lvyou Road, Jinan, Shandong 250104, CHINA Powered by

Qilu Pharmaceutical Acquired an Exclusive Right for the Development and Commercialization of Vicineum™ in Greater China

Release time:

Qilu Pharmaceutical announced an exclusive license agreement with Sesen Bio for the development and commercialization of Vicineum™ in Greater China on July 31st, 2020. Vicineum™ is used for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) and other types of cancer.

“Qilu is well-respected for their commercialization and manufacturing expertise, and this partnership marks an important milestone in realizing what we believe to be a significant market opportunity for Vicineum” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

“Sesen is the ideal partner for us with the unique scientific research advantage in NMIBC” said Yan Li, chief executive officer of Qilu Pharmaceutical. “We look forward to working with Sesen and The National Medical Products Administration to bring Vicineum to patients who urgently need better therapies for BCG unresponsive non-muscle invasive bladder cancer in China.”